FDA Approves ASCENIV™, A Novel Intravenous Immune Globulin
See the Press Release
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.
ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections
ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections:READ MOREADMA Receives Department of Health and Human Services U.S. License
ADMA Receives Department of Health and Human Services U.S. License:READ MOREFDA Approves ASCENIV™, a Novel Intravenous Immune Globulin
FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin:READ MORE